Treatment of Active Cutaneous Lupus Erythematosus in Patients with Systemic Lupus Erythematosus

Active cutaneous involvement is a clinically significant manifestation in patients with systemic lupus erythematosus. Managing active skin disease in this population requires a structured, stepwise approach tailored to disease severity and patient characteristics.

Clinical Scenario

This protocol addresses active cutaneous lupus erythematosus arising in the setting of systemic lupus erythematosus — a scenario where skin disease activity warrants targeted therapeutic intervention alongside management of the underlying systemic condition.

Treatment Approach (partial overview)

First-line management of active skin disease in SLE centres on topical agents and antimalarials as foundational therapies, with systemic options available when needed.

The complete regimen, sequencing, and full range of options are available in the structured protocol below.

Instant Access to Structured Evidence-Based Regimens

References

Treatment of active skin disease should include topical agents (glucocorticoids, calcineurin inhibitors) (2b/B), antimalarials (hydroxychloroquine, chloroquine) (1a/A), and/or systemic glucocorticoids (4/C) as needed, with methotrexate (1b/B), mycophenolate (4/C), anifrolumab (1a/A), or belimumab (1a/B) considered as second-line therapy.
HCQ is the antimalarial of choice, but chloroquine may be used in the settings discussed earlier.

DOI: 10.1136/ard-2023-224762

View source ↗